Asthma is disease manifested by chronic inflammation exacerbated by environmental insults such as allergens, infectious agents and irritants. The innate and adaptive host responses recognize and eradicate the effect of these insults to restore tissue integrity and homeostasis. In our proposal, we focus on the critical innate immune factors surfactant protein A (SP-A), a lipid constituent of surfactant, palmitoyl-oleoyl- phosphatidylglycerol (POPG) and Toll-like receptor interacting protein (Tollip). We show that these mediators each perform critical negative regulatory functions that synergize to offer protection from type 2 inflammation and viral exacerbations. SP-A modulates inflammation associated with type 2 inflammation and viral infections but exhibits genetic heterogeneity altering its function. Tollip, a 30 kDa adaptor protein that is also genetically heterogeneous, is recognized as a negative regulator of toll-like receptor (TLR) signaling. A phospholipid contained in surfactant, POPG is known to play a critical role in regulating innate immunity by inhibiting activation of multiple TLRs. Our central hypothesis to be tested is that dysfunction of SP-A, Tollip and POPG occurs as a consequence of genetic polymorphisms and degradative events which significantly alter their function in the setting of asthma and viral infection, leading to exacerbations and persistence of inflammation. With an underpinning of innate immune dysfunction, the projects utilize distinct but overlapping clinically relevant models of exacerbations in asthma (rhinovirus (RV), respiratory syncytial virus (RSV)), type 2 inflammation (IL-13 exposure, HDM animal models) from distinct molecular perspectives (SP-A, Tollip, POPG), effectively creating a network rather than linear approach to understanding the mechanism(s) of innate immune dysfunction in type 2 inflammation and asthma exacerbations. This program proposes three interrelated projects: Project 1 will determine how SP-A suppresses allergic inflammation through disruption of IL-13-dependent signaling pathways, but due to genetic heterogeneity, its function is impaired in asthma. Specific SP-A peptides can rescue this dysfunction, offering a novel therapeutic approach for asthma. Project 2 will determine the relationship between genetically determined variations in Tollip expression and airway responses to viral infections in the setting of type 2 inflammation. Project 3 will critically test the activity of POPG and SP-A as novel endogenous molecular mechanisms for disrupting infections due to RV and RSV, two viruses known to exacerbate asthma. We also include two cores: an Administrative Core and a Clinical Core, both which serve all projects equally and are responsible for the scientific, advisory, fiscal, human subject and data management/statistical aspects of the program. In this U19 program, we propose novel mechanisms of innate immune dysfunction and potential treatments that not only modulate the resolution of allergic inflammation, but regulate host-pathogen interactions in the setting of allergic inflammation.

Public Health Relevance

Overall Narrative Asthma is a disease characterized by wheezing, chest tightness and cough that can lead to exacerbations, hospitalization and sometimes death. We do not completely understand the reasons behind persistent inflammation or why viral infections occur more frequently in patients with asthma. We hypothesize in this Asthma and Allergic Diseases Cooperative Research Center (AADCRC) U19 program, that specific aspects of the host response which are surfactant protein A, Toll interacting protein (Tollip) and palmitoyl-oleoyl- phosphatidylglycerol (POPG) are dysfunctional in asthma. These mediators have complementary and overlapping functions and we explore reasons for the dysfunction, but also evaluate two therapies that can correct the dysfunction in these mediators. This program will benefit public health as it can lead to therapies to reduce exacerbations and resolve persistent inflammation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI125357-05
Application #
9971434
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Minnicozzi, Michael
Project Start
2016-07-01
Project End
2021-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Arizona
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Dakhama, Azzeddine; Chu, Hong Wei (2018) The Use of CRISPR-Cas9 Technology to Reveal Important Aspects of Human Airway Biology. Methods Mol Biol 1799:371-380
Ito, Yoko; Schaefer, Niccolette; Sanchez, Amelia et al. (2018) Toll-Interacting Protein, Tollip, Inhibits IL-13-Mediated Pulmonary Eosinophilic Inflammation in Mice. J Innate Immun 10:106-118
Ito, Yoko; Al Mubarak, Reem; Roberts, Nicole et al. (2018) IL-13 induces periostin and eotaxin expression in human primary alveolar epithelial cells: Comparison with paired airway epithelial cells. PLoS One 13:e0196256
Lugogo, Njira; Francisco, Dave; Addison, Kenneth J et al. (2018) Obese asthmatic patients have decreased surfactant protein A levels: Mechanisms and implications. J Allergy Clin Immunol 141:918-926.e3
Roberts, Nicole; Al Mubarak, Reem; Francisco, David et al. (2018) Comparison of paired human nasal and bronchial airway epithelial cell responses to rhinovirus infection and IL-13 treatment. Clin Transl Med 7:13
Kummarapurugu, Apparao B; Zheng, Shuo; Ledford, Julie et al. (2018) High-Mobility Group Box 1 Upregulates MUC5AC and MUC5B Expression in Primary Airway Epithelial Cells. Am J Respir Cell Mol Biol 58:126-128
Carr, Tara F; Kraft, Monica (2017) Management of Severe Asthma before Referral to the Severe Asthma Specialist. J Allergy Clin Immunol Pract 5:877-886
Jiang, Di; Matsuda, Jennifer; Berman, Reena et al. (2017) A novel mouse model of conditional IRAK-M deficiency in myeloid cells: application in lung Pseudomonas aeruginosa infection. Innate Immun 23:206-215
Noutsios, George T; Willis, Amanda L; Ledford, Julie G et al. (2017) Novel role of surfactant protein A in bacterial sinusitis. Int Forum Allergy Rhinol 7:897-903
Huang, C; Jiang, D; Francisco, D et al. (2016) Tollip SNP rs5743899 modulates human airway epithelial responses to rhinovirus infection. Clin Exp Allergy 46:1549-1563